July 02, 2019, Source: Seelos Therapeutics, Inc.
NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that they have received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for Seelos’ U.S. Patent Application for SLS-005 (trehalose) for treating Friedreich Ataxia (FA).
Friedreich Ataxia (FA) is a rare inherited neuromuscular disease affecting the nervous system resulting in issues with balance and coordination, spinal deformity, cardiovascular issues and in some patients can lead to the onset of diabetes. It is among the group of neurological conditions related by the commonality of protein aggregations, such as Sanfilippo syndrome, Oculopharyngeal Muscular Dystrophy (OPMD) and Huntington's disease. FA affects about one in 50,000 people worldwide, making it the most common in a group of related disorders called hereditary ataxias. More information about FA can be found at: https://www.ninds.nih.gov/disorders/patient-caregiver-education/fact-sheets/friedreichs-ataxia-fact-sheet
SLS-005 already has orphan indication for Spinocerebellar Ataxia (SCA3) and Seelos is currently developing SLS-005 for Sanfilippo syndrome followed by the OPMD indication.
Related:
Bioblast Pharma Announces Sale of its Trehalose Clinical Development Programs to Seelos Therapeutics.
Tel Aviv, Israel, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. ( Nasdaq: ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced the sale of its Trehalose clinical development programs (including its advanced phase 2 clinical program of Trehalose to treat Oculoharyngeal Muscular Dystrophy (OPMD) to Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company.
Subscribe to:
Posts (Atom)
